echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Promising results for iberdomide in stage II systemic lupus erythematosus

    NEJM: Promising results for iberdomide in stage II systemic lupus erythematosus

    • Last Update: 2022-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    There are abnormalities in the regulation of multiple innate and adaptive immune pathways in patients with systemic lupus erythematosus (SLE)


    Immuno -Iberdomide is a novel oral cereblon E3 ubiquitin ligase immunomodulator that promotes proteasomal degradation of Ikaros and Aiolos


    In the phase II clinical study, patients were randomized to receive either oral Iberdomide (0.


    A total of 288 patients were enrolled in the study, of which 81 received Iberdomide at a dose of 0.


    At 24 weeks, the proportion of patients who achieved an SRI-4 response was 54% in the iberdomide 0.


    Phase II clinical studies have confirmed that iberdomide 0.


    Iberdomide 0.


    Original source:

    Joan T.


    Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.